Protalix BioTherapeutics Stock (AMEX: PLX)

Protalix BioTherapeutics

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BUKS

TGEN

The Dow Jones closed lower by around 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Protalix BioTherapeutics And 2 Other Penny Stocks Insiders Are Buying

Biotech

Health Care

General

FOLD

The FDA approved Chiesi Group and Protalix BioTherapeutics Inc&#39;s (NASDAQ: PLX) Elfabrio (pegunigalsidase alfa-iwxj) for treating adult 

Fabry Disease Treatment Showdown: Protalix Bio&#39;s Elfabrio Joins the Ranks of Sanofi and Amicus Therapeutics

Earnings

Equities

Protalix Clocks 40% Decline In Q1 Revenues Reflecting Lower Sales To Brazil

Protalix BioTherapeutics, Inc. (DE) Common Stock

Protalix BioTherapeutics Inc

Piolax Inc

Pluxee NV

PLx Pharma Inc

PLx Pharma Winddown Corp

Plexus Corp

Press Releases

Protalix BioTherapeutics Reports Second Quarter 2024 Financial and Business Results

Protalix BioTherapeutics Announces Repayment of Outstanding Senior Secured Convertible Promissory Notes

Protalix BioTherapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Kaskela Law LLC Announces Shareholder Investigation of Protalix BioTherapeutics, Inc. (NYSE: PLX) and Encourages Investors to Contact the Firm

Small Cap

Protalix BioTherapeutics to Present Phase I PRX-115 Data in Late-Breaking Poster at ACR Convergence 2024

Fintech

Protalix BioTherapeutics to Announce Third Quarter 2024 Financial and Business Results on November 14, 2024

Protalix BioTherapeutics Reports Third Quarter 2024 Financial and Business Results

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce Validation of Variation Submission by European Medicines Agency for pegunigalsidase alfa

Protalix BioTherapeutics Issues 2025 Letter to Stockholders

Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Alector

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

C4 Therapeutics

Cargo Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Genfit

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics

Inhibrx Biosciences

INmune Bio

Innate Pharma S.A. - American Depositary Shares

Innate Pharma

Inventiva S.A. - American Depository Shares

Inventiva

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Macrogenics

Molecular Partners AG - American Depositary Shares

Molecular Partners

Nanobiotix

Nuvectis Pharma

Ocugen

Puma Biotechnology

ProKidney Corp. - Class A Ordinary Shares

ProKidney

Renovaro

TriSalus Life Sciences, Inc. - Common Stock

TriSalus Life Sciences

HC Wainwright & Co.

Comments

Protalix BioTherapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga